rinfabate (rhIGFBP-3) / Insmed - LARVOL DELTA

IGFBP3 Promotes Resistance to Olaparib via Modulating EGFR Signaling in Advanced Prostate Cancer (SBUR 2022) - "Our findings demonstrated that inhibiting IGFBP3 and EGFR aids in PARPi sensitivity in the resistant setting. Future work will utilize OlapR models to study how the IGFBP3/EGFR/DNA-PKcs protein complex promotes the development of resistance. Understanding the role of IGFBP3 in PARPi resistance will enhance our ability to re-sensitize resistant CRPC to PARPi therapeutics."

FDA lifts hold on trials of Insmed lung drug, shares up (Reuters) - Insmed stopped pursuing the development of its cancer products rhIGFBP-3 & INSM-18

Drug discontinuation • Oncology